高质量国产创新药出海事件再临！港股创新药ETF(159567)跟踪指数趋势上行，康方生物、康希诺生物、再鼎医药领涨。

有连云06-24

2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，6月21日，某港股创新药企宣布，合作伙伴已收到欧盟委员会的通知，批准呋喹替尼上市，呋喹替尼作为欧盟十多年来首个针对mCRC的新型靶向疗法，在后线结直肠癌领域具备差异化治疗优势，其临床效果数据表现较好。伴随...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2445909258?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-24 10:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2445909258","market":"hk","top_or_hot":-1,"title":"高质量国产创新药出海事件再临！港股创新药ETF(159567)跟踪指数趋势上行，康方生物、康希诺生物、再鼎医药领涨。","media":"有连云","content":"<div>\n<p>2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，6月21日，某港股创新药企宣布，合作伙伴已收到欧盟委员会的通知，批准呋喹替尼上市，呋喹替尼作为欧盟十多年来首个针对mCRC的新型靶向疗法，在后线结直肠癌领域具备差异化治疗优势，其临床效果数据表现较好。伴随...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高质量国产创新药出海事件再临！港股创新药ETF(159567)跟踪指数趋势上行，康方生物、康希诺生物、再鼎医药领涨。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高质量国产创新药出海事件再临！港股创新药ETF(159567)跟踪指数趋势上行，康方生物、康希诺生物、再鼎医药领涨。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-24 10:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b><strong>有连云</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，6月21日，某港股创新药企宣布，合作伙伴已收到欧盟委员会的通知，批准呋喹替尼上市，呋喹替尼作为欧盟十多年来首个针对mCRC的新型靶向疗法，在后线结直肠癌领域具备差异化治疗优势，其临床效果数据表现较好。伴随...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b","article_id":"2445909258","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2445909258","pubTimestamp":1719195716,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额达到6194万元。伴随我国药企创新实力的逐步提升，以呋喹替尼为代表的我国高质量国产创新药出海正当时，可重点围绕景气度边际转暖的赛道的优质公司进行布局。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688185":"康希诺","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","06185":"康希诺生物","LU1720050803.USD":"安联全方位中国股票基金","ZLAB":"再鼎医药","BK1191":"制药","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","06978":"永泰生物-B","BK1515":"抗疫概念","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1588":"回港中概股","09688":"再鼎医药","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD"},"translate_title":"The event of high-quality domestic innovative drugs going overseas is coming again! The Hong Kong stock innovative drug ETF (159567) tracks the upward trend of the index, led by Akeso Bio, CanSino Biologics, and Zai Lab.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06978":1,"09688":1,"09926":1,"06185":1,"ZLAB":0.9},"content_text":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF（159567）市场热度较高，过去5个交易日日均成交额达到6194万元。平安证券表示，6月21日，某港股创新药企宣布，合作伙伴已收到欧盟委员会的通知，批准呋喹替尼上市，呋喹替尼作为欧盟十多年来首个针对mCRC的新型靶向疗法，在后线结直肠癌领域具备差异化治疗优势，其临床效果数据表现较好。伴随我国药企创新实力的逐步提升，以呋喹替尼为代表的我国高质量国产创新药出海正当时，可重点围绕景气度边际转暖的赛道的优质公司进行布局。相关产品：港股创新药ETF（159567）本条资讯内容与数据仅供参考，不构成投资建议。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445909258"}